NICE approval for new overactive bladder and diabetes drugs
First-in-class treatments for overactive bladder and type 2 diabetes can now be...
Jump to:
The award-winning MIMS app is available for iPhone, iPad and Android, and includes our popular drug comparison tables for easy reference.
With more than 19,000 downloads and a 4-star rating, the MIMS app provides a convenient companion to the print and online versions of MIMS.
Click here to watch the MIMS app video
Colobreathe (colistimethate sodium) is an inhaled dry powder formulation of colistimethate for...
First-in-class treatments for overactive bladder and type 2 diabetes can now be...
Children under four months of age are to be vaccinated against rotavirus...
The MIMS contraceptives table has been updated to include price information, in...
Stribild is a combination tablet containing elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil,...
Other new launches, licence changes and updates relevant to general practice.
The Scottish Medicines Consortium has issued its latest set of recommendations on...
The following products have become available for the UK market in 2013....
The following products are no longer available and have been removed from...
Selincro (nalmefene) is indicated in combination with psychosocial support for the reduction...
MolluDab is a topical solution of potassium hydroxide 5% for direct application...
Intermune has launched Esbriet (pirfenidone) for the treatment of mild to moderate...
Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.
Supplied by the National
Travel Health Network
and Centre (NaTHNaC)